Gilead Sciences to Acquire Immunomedics
Trodelvy will Accelerate Gilead’s Emerging and Complementary Oncology Pipeline
15-Sep-2020 -
Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both ...
acquisitions
breast cancer
GILEAD Sciences